Skip to main content

Tenecteplase Has Similar Safety to TPA for Acute Ischemic Stroke

Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 17, 2024.

By Elana Gotkine HealthDay Reporter

THURSDAY, Oct. 17, 2024 -- For patients with acute ischemic stroke (AIS), tenecteplase (TNK) has improved functional outcome and reduced disability and similar safety to alteplase (tissue plasminogen activator [TPA]), according to a study published online Oct. 16 in Neurology.

Lina Palaiodimou, M.D., Ph.D., from the National and Kapodistrian University of Athens in Greece, and colleagues conducted a systematic review and meta-analysis of all available randomized controlled trials (RCTs) that examined the efficacy and safety of TNK 0.25 mg/kg versus TPA for treatment of AIS within 4.5 hours of onset. Data were included for 11 RCTs, with 3,788 patients treated with TNK and 3,757 patients treated with TPA.

The researchers found that compared with TPA, TNK was associated with a higher likelihood of excellent functional outcome (risk ratio, 1.05) and reduced disability at three months (common odds ratio, 1.10), while the groups had similar improved functional outcome. Similar rates of symptomatic intracranial hemorrhage and three-month mortality were observed in the groups. Statistical significance in achieving an excellent functional outcome at three months was retained for the original TNK when stratified for TNK regimen (original versus biocopy; risk ratio, 1.05).

"It demonstrates that TNK is associated with better clinical outcomes, showing superiority over TPA in achieving excellent functional outcome and reduced disability at three months. These findings support transitioning to TNK in clinical practice," the authors write.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted October 2024

Read this next

Most Patients Newly Diagnosed With A-Fib Do Not Receive Anticoagulants

WEDNESDAY, April 23, 2025 -- For patients newly diagnosed with atrial fibrillation (AF) during hospitalization for other causes, most are not dispensed anticoagulants in the year...

Age-Adjusted Ischemic Stroke Mortality Increased Since 2009

FRIDAY, April 18, 2025 -- Patterns of mortality and end-of-life care have changed among U.S. ischemic stroke patients, with increases in mortality seen across all urbanization...

Study Sheds Light on Role of Risk Factors in Young-Onset Cryptogenic Ischemic Stroke

THURSDAY, April 17, 2025 -- Traditional risk factors contribute to young-onset cryptogenic ischemic stroke (CIS) without patent foramen ovale (PFO), while nontraditional risk...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.